Jon Florholmen
Impact in
- Genetics top 1%
- Inflammatory Bowel Disease
- Immunology top 2%
- Biosimilars and Bioanalytical Methods
- IL-33, ST2, and ILC Pathways
- Psoriasis: Treatment and Pathogenesis
Papers in
- Genetics 30
- Inflammatory Bowel Disease 30
-
- IL-33, ST2, and ILC Pathways 3
- Co-authors
- Rasmus Goll (31 shared papers)Guanglin Cui (23 shared papers)Trine Olsen (12 shared papers)Aping Yuan (8 shared papers)Barthold Vonen (5 shared papers)Jan‐Magnus Kvamme (5 shared papers)Ruth Hracky Paulssen (8 shared papers)Anne Husebekk (3 shared papers)
In The Last Decade
Jon Florholmen
62 papers receiving 2.8k citations
Jon Florholmen's Hit Papers
Peers
Comparison fields: 5 of 79
- Genetics 1.1k
- Immunology 535
- Gastroenterology 46
- Oncology 117
- Rheumatology 48
Countries citing papers authored by Jon Florholmen
This map shows the geographic impact of Jon Florholmen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Florholmen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Florholmen more than expected).
Fields of papers citing papers by Jon Florholmen
This network shows the impact of papers produced by Jon Florholmen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Florholmen. The network helps show where Jon Florholmen may publish in the future.
Co-authors
The 25 scholars most cited alongside Jon Florholmen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 63 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial Hit paper breakdown → | 2017 | 656 |
| 2 | 2014 | 139 | |
| 3 | 2007 | 129 | |
| 4 | 2011 | 120 | |
| 5 | 2011 | 97 | |
| 6 | 2014 | 88 | |
| 7 | 2010 | 82 | |
| 8 | 2019 | 80 | |
| 9 | 2021 | 77 | |
| 10 | 2012 | 72 | |
| 11 | 2009 | 69 | |
| 12 | 2012 | 65 | |
| 13 | 2017 | 63 | |
| 14 | 2006 | 58 | |
| 15 | 2009 | 55 | |
| 16 | 2020 | 50 | |
| 17 | 2013 | 47 | |
| 18 | 2014 | 43 | |
| 19 | 2018 | 43 | |
| 20 | 2008 | 42 |
About Jon Florholmen
Jon Florholmen is a scholar working on Genetics, Immunology, Gastroenterology, Surgery and Hepatology, having authored 63 papers that have together received 2.8k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (30 papers), Helicobacter pylori-related gastroenterology studies (4 papers), IL-33, ST2, and ILC Pathways (3 papers), Gastrointestinal motility and disorders (2 papers), Pregnancy and preeclampsia studies (1 paper), Trace Elements in Health (1 paper), Epigenetics and DNA Methylation (1 paper) and Hepatitis C virus research (1 paper). The work is most often cited by research in Genetics (1.1k citations), Immunology (535 citations), Gastroenterology (46 citations), Oncology (117 citations) and Rheumatology (48 citations). Jon Florholmen has collaborated with scholars based in Norway, China and Denmark. Frequent co-authors include Rasmus Goll, Guanglin Cui, Trine Olsen, Aping Yuan, Barthold Vonen, Jan‐Magnus Kvamme, Ruth Hracky Paulssen, Anne Husebekk, Christopher Graham Fenton and Eyvind J. Paulssen. Their work appears in journals such as Scandinavian Journal of Gastroenterology, Scientific Reports, Journal of Crohn s and Colitis, Inflammatory Bowel Diseases and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.